Objective responses were observed in 17 ( 31.5 % ) of 54 patients randomly assigned to gemcitabine-docetaxel plus placebo and 19 ( 35.8 % ) of 53 patients randomly assigned to gemcitabine-docetaxel plus bevacizumab .